Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France.

Nagar SP, Mytelka DS, Candrilli SD, D'yachkova Y, Lorenzo M, Kasper B, Lopez-Martin JA, Kaye JA.

Sarcoma. 2018 May 24;2018:5467057. doi: 10.1155/2018/5467057. eCollection 2018.

2.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Jun 9. pii: S0169-5002(18)30416-1. doi: 10.1016/j.lungcan.2018.06.007. [Epub ahead of print]

3.

Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom.

La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L.

Eur J Cancer Care (Engl). 2018 Jun 21:e12862. doi: 10.1111/ecc.12862. [Epub ahead of print]

PMID:
29927010
4.

Epidemiology of Adult Soft-Tissue Sarcomas in Germany.

Saltus CW, Calingaert B, Candrilli S, Lorenzo M, D'yachkova Y, Otto T, Wagner U, Kaye JA.

Sarcoma. 2018 Apr 4;2018:5671926. doi: 10.1155/2018/5671926. eCollection 2018.

5.

Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom.

Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A.

Epidemiology. 2018 Sep;29(5):e41-e42. doi: 10.1097/EDE.0000000000000856. No abstract available.

PMID:
29794511
6.

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States.

Zuluaga-Sanchez S, Hess LM, Wolowacz SE, D'yachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D.

Sarcoma. 2018 Mar 26;2018:6703963. doi: 10.1155/2018/6703963. eCollection 2018.

7.

Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas.

Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA.

Clin Sarcoma Res. 2018 May 3;8:8. doi: 10.1186/s13569-018-0094-x. eCollection 2018.

8.

Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study.

Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegård A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S.

Drugs Real World Outcomes. 2018 May 7. doi: 10.1007/s40801-018-0133-1. [Epub ahead of print]

9.

A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).

Castellsague J, Kuiper JG, Pottegård A, Anveden Berglind I, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MP, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S.

Clin Epidemiol. 2018 Mar 13;10:299-310. doi: 10.2147/CLEP.S146442. eCollection 2018.

10.

Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.

Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA.

Int J Gynecol Cancer. 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222.

PMID:
29538247
11.

Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study.

Hallas J, Margulis AV, Pottegård A, Kristiansen NS, Atsma WJ, Appenteng K, de Vogel S, Kaye JA, Perez-Gutthann S, Arana A.

Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):612-619. doi: 10.1111/bcpt.12965. Epub 2018 Feb 22.

PMID:
29345103
12.

Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER-2- Breast Cancer: A Multicountry Retrospective Medical Record Review.

Kurosky SK, Mitra D, Zanotti G, Kaye JA.

Clin Breast Cancer. 2018 Aug;18(4):e529-e538. doi: 10.1016/j.clbc.2017.10.008. Epub 2017 Oct 14.

PMID:
29199086
13.

Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom.

Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A.

Epidemiology. 2018 Mar;29(2):308-313. doi: 10.1097/EDE.0000000000000786.

14.

Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.

Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA.

Support Care Cancer. 2018 Feb;26(2):539-548. doi: 10.1007/s00520-017-3863-9. Epub 2017 Sep 18.

PMID:
28921379
15.

Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).

Grange F, Mohr P, Harries M, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz S, Kontoudis I.

Melanoma Res. 2017 Dec;27(6):607-618. doi: 10.1097/CMR.0000000000000372.

PMID:
28800027
16.

Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey.

Brett Hauber A, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D.

Support Care Cancer. 2018 Jan;26(1):251-260. doi: 10.1007/s00520-017-3841-2. Epub 2017 Aug 7.

PMID:
28785862
17.

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma.

Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D.

J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760. Epub 2017 May 21.

18.

Clinical outcomes of female breast cancer according to BRCA mutation status.

Cronin-Fenton DP, Kjærsgaard A, Nørgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L, Telford C, Lewis J, Tyczynski JE, Sørensen HT.

Cancer Epidemiol. 2017 Aug;49:128-137. doi: 10.1016/j.canep.2017.05.016. Epub 2017 Jun 8.

PMID:
28601786
19.

Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: A retrospective and prospective observational study (MELABIS).

Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, Kaye JA, Kontoudis I.

Int J Clin Pract. 2017 May;71(5). doi: 10.1111/ijcp.12946.

20.

Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA.

Curr Med Res Opin. 2017 Aug;33(8):1457-1466. doi: 10.1080/03007995.2017.1325730. Epub 2017 May 16. Review.

PMID:
28463012
21.

Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.

Kaye JA, Margulis AV, Fortuny J, McQuay LJ, Plana E, Bartsch JL, Bui CL, Perez-Gutthann S, Arana A.

Pharmacotherapy. 2017 Jun;37(6):673-683. doi: 10.1002/phar.1932. Epub 2017 May 29.

22.

A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma.

Colosia A, Khan S, Hackshaw MD, Oglesby A, Kaye JA, Skolnik JM.

Sarcoma. 2016;2016:3597609. doi: 10.1155/2016/3597609. Epub 2016 Jul 19. Review.

23.

"Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.

Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D.

Support Care Cancer. 2016 Sep;24(9):3889-96. doi: 10.1007/s00520-016-3193-3. Epub 2016 Apr 23.

PMID:
27108262
24.

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

Davis KL, Côté I, Kaye JA, Mendelson E, Gao H, Perez Ronco J.

Adv Hematol. 2015;2015:848473. doi: 10.1155/2015/848473. Epub 2015 Nov 9.

25.

Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.

Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M.

J Oncol Pharm Pract. 2016 Oct;22(5):666-78. doi: 10.1177/1078155215603230. Epub 2015 Aug 28. Review.

PMID:
26320127
26.

Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.

Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B.

J Gastric Cancer. 2015 Jun;15(2):87-104. doi: 10.5230/jgc.2015.15.2.87. Epub 2015 Jun 30.

27.

Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.

Smyth EN, Bapat B, Ball DE, André T, Kaye JA.

Clin Ther. 2015 Jun 1;37(6):1301-16. doi: 10.1016/j.clinthera.2015.03.016. Epub 2015 Apr 20.

28.

Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.

Davis KL, Goyal RK, Able SL, Brown J, Li L, Kaye JA.

Lung Cancer. 2015 Feb;87(2):176-85. doi: 10.1016/j.lungcan.2014.11.002. Epub 2014 Nov 8.

PMID:
25532680
29.

Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.

Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008. Epub 2014 Oct 2. Review.

PMID:
25445467
30.

Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.

Whiteley J, Iyer S, Candrilli SD, Kaye JA.

Curr Med Res Opin. 2015 Feb;31(2):299-314. doi: 10.1185/03007995.2014.991817. Epub 2015 Jan 30.

PMID:
25427232
31.

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer.

Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ.

Cancer Manag Res. 2014 Oct 23;6:437-49. doi: 10.2147/CMAR.S63603. eCollection 2014. Review.

32.

Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents.

Xu H, Kaye JA, Saltus CW, Crawford J, Gasal E, Goodnough LT.

Expert Rev Hematol. 2014 Oct;7(5):617-33. doi: 10.1586/17474086.2014.943730. Epub 2014 Aug 1. Review.

PMID:
25081548
33.

Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review.

Njue A, Colosia A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12.e7. doi: 10.1016/j.clml.2014.03.006. Epub 2014 Jun 11. Review.

PMID:
25052050
34.

Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.

Kaye JA, Castellsague J, Bui CL, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, Quinlan S, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander MA, Perez-Gutthann S.

Pharmacotherapy. 2014;34(4):336-49. doi: 10.1002/phar.1367. Epub 2013 Nov 5.

35.

Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.

Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-355.e6. doi: 10.1016/j.clml.2014.02.012. Epub 2014 Mar 1. Review.

PMID:
24768510
36.

Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.

Mitra D, Kaye JA, Piecoro LT, Brown J, Reith K, Mughal TI, Sarlis NJ.

Cancer Med. 2013 Dec;2(6):889-98. doi: 10.1002/cam4.136. Epub 2013 Oct 5.

37.

Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users.

Bui CL, Kaye JA, Castellsague J, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, Quinlan SC, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander MA, Perez-Gutthann S.

Curr Drug Saf. 2014 Mar;9(1):23-8.

PMID:
24111729
38.

Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.

Meyers J, Yu Y, Kaye JA, Davis KL.

Appl Health Econ Health Policy. 2013 Jun;11(3):275-86. doi: 10.1007/s40258-013-0032-2.

PMID:
23677706
39.

A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.

Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA.

J Med Econ. 2013;16(6):720-35. doi: 10.3111/13696998.2013.782034. Epub 2013 Apr 12.

PMID:
23452298
40.

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C.

Onco Targets Ther. 2012;5:287-96. doi: 10.2147/OTT.S36683. Epub 2012 Oct 23.

41.

Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.

Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA.

Int J Hematol. 2012 May;95(5):535-44. doi: 10.1007/s12185-012-1043-8. Epub 2012 Mar 30.

PMID:
22461032
42.

Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study.

Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA.

Int J Hematol. 2012 Mar;95(3):263-73. doi: 10.1007/s12185-012-1010-4. Epub 2012 Feb 17.

PMID:
22351162
43.

Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.

Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, Molnár I, Sherrill B.

Int J Colorectal Dis. 2012 May;27(5):623-34. doi: 10.1007/s00384-011-1349-7. Epub 2011 Nov 12.

PMID:
22076612
44.

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.

Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S.

Breast Cancer Res Treat. 2011 Jan;125(2):431-9. doi: 10.1007/s10549-010-1222-3. Epub 2010 Nov 3.

PMID:
21042933
45.

A review and characterization of the various perceptions of quality cancer care.

Colosia AD, Peltz G, Pohl G, Liu E, Copley-Merriman K, Khan S, Kaye JA.

Cancer. 2011 Mar 1;117(5):884-96. doi: 10.1002/cncr.25644. Epub 2010 Oct 11. Review.

46.

ORTHO EVRA and venous thromboembolism: an update.

Jick SS, Hagberg KW, Kaye JA.

Contraception. 2010 May;81(5):452-3. doi: 10.1016/j.contraception.2009.12.016. Epub 2010 Jan 27. No abstract available.

PMID:
20399954
47.

Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database.

Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, Fryzek J, Kaye JA.

Br J Haematol. 2010 Jun;149(6):855-64. doi: 10.1111/j.1365-2141.2010.08176.x. Epub 2010 Apr 4.

PMID:
20377590
48.

Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.

Jick SS, Hagberg KW, Hernandez RK, Kaye JA.

Contraception. 2010 Jan;81(1):16-21. doi: 10.1016/j.contraception.2009.07.004.

PMID:
20004268
49.

The REMS publication paradox.

Andrews EB, Kaye JA, Van Bennekom C.

Oncology (Williston Park). 2009 Jul;23(8):715-7. Review. No abstract available.

50.

The risk of unintended pregnancies in users of the contraceptive patch compared to users of oral contraceptives in the UK General Practice Research Database.

Jick SS, Hagberg KW, Kaye JA, Jick H.

Contraception. 2009 Aug;80(2):142-51. doi: 10.1016/j.contraception.2009.02.013. Epub 2009 Apr 25.

PMID:
19631789

Supplemental Content

Loading ...
Support Center